Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Progesterone and Synthetic Progestin Controversies

Progesterone and Synthetic Progestin Controversies Letters confirm the study results of the PLCO trial that biopsy at a PSA COMMENT & RESPONSE threshold of 4.0 ng/mL did not decrease prostate cancer– specific or overall mortality. For prostate cancer–specific mor- tality, the trend was toward increased mortality at the cutoff, To the Editor Scientific veracity is required for translational which is opposite of what would be expected if there were a research. Biological systems of human relevance must benefit to screening. model clinical results. The Editorial by Joshi et al offered a molecular mechanism, derived from progesterone action in Interpreting clinical data using RD has many potential ap- plications in medicine since treatment decisions are often based mice, to explain the current update of the Women’s Health Initiative (WHI). The role of progesterone and pregnancy to on discrete cutoffs in continuous data. enhance rodent mammary carcinogenesis has been known for half a century but did not translate to postmenopausal Jonathan Shoag, MD Joshua Halpern, MD women. Specifically, antiprogestin therapies may have merit but were tested unsuccessfully decades ago. Perhaps, a dif- Brian Eisner, MD Richard Lee, MD ferent strategy has merit. For scientific veracity, any mecha- nism offered must explain the entire results of the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Progesterone and Synthetic Progestin Controversies

Gompel, Anne; Plu-Bureau, Geneviève
JAMA Oncology , Volume 1 (7) – Oct 1, 2015
Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/progesterone-and-synthetic-progestin-controversies-2BNrFo3eMR

References (23)

Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2015.2283
pmid
26448287
Publisher site
See Article on Publisher Site

Abstract

Letters confirm the study results of the PLCO trial that biopsy at a PSA COMMENT & RESPONSE threshold of 4.0 ng/mL did not decrease prostate cancer– specific or overall mortality. For prostate cancer–specific mor- tality, the trend was toward increased mortality at the cutoff, To the Editor Scientific veracity is required for translational which is opposite of what would be expected if there were a research. Biological systems of human relevance must benefit to screening. model clinical results. The Editorial by Joshi et al offered a molecular mechanism, derived from progesterone action in Interpreting clinical data using RD has many potential ap- plications in medicine since treatment decisions are often based mice, to explain the current update of the Women’s Health Initiative (WHI). The role of progesterone and pregnancy to on discrete cutoffs in continuous data. enhance rodent mammary carcinogenesis has been known for half a century but did not translate to postmenopausal Jonathan Shoag, MD Joshua Halpern, MD women. Specifically, antiprogestin therapies may have merit but were tested unsuccessfully decades ago. Perhaps, a dif- Brian Eisner, MD Richard Lee, MD ferent strategy has merit. For scientific veracity, any mecha- nism offered must explain the entire results of the

Journal

JAMA Oncology – American Medical Association

Published: Oct 1, 2015

There are no references for this article.